Granulocyte macrophage-colony stimulating factor (GM-CSF) and sucralfate in prevention of radiation-induced mucositis: a prospective randomized study.

To compare subcutaneously given molgramostim (GM-CSF) and sucralfate mouth washings to sucralfate mouth washings in prevention of radiation-induced mucositis.
Forty head and neck cancer patients were randomly assigned to use either GM-CSF and sucralfate (n = 20) or sucralfate alone (n = 20) during radiotherapy. Sucralfate was used as 1.0 g mouth washing 6 times daily after the first 10 Gy of radiotherapy, and 150-300 microg GM-CSF was given subcutaneously. The grade of radiation mucositis and blood cell counts were monitored weekly. Salivary lactoferrin was measured as a surrogate marker for oral mucositis.
We found no significant difference between the molgramostim and the control groups in the oral mucositis grade, oral pain, use of analgesic drugs, weight loss, or survival. The median maximum neutrophil counts (median, 9.2 x 10(9)/L vs. 5.9 x 10(9)/L, p = 0.0005), eosinophil counts (median, 1.3 x 10(9)/L vs. 0.2 x 10(9)/L, p = 0.0004), and salivary lactoferrin concentrations were higher in patients who received GM-CSF. The most common toxicities in the GM-CSF plus sucralfate group were skin reactions at the GM-CSF injection site (65%), fever (30%), bone pain (25%), and nausea (15%), whereas the toxicity of sucralfate given alone was minimal.
We found no evidence indicating that subcutaneously given GM-CSF reduces the severity of radiation-induced mucositis.
AuthorsT A Makkonen, H Minn, A Jekunen, P Vilja, J Tuominen, H Joensuu
JournalInternational journal of radiation oncology, biology, physics (Int J Radiat Oncol Biol Phys) Vol. 46 Issue 3 Pg. 525-34 (Feb 1 2000) ISSN: 0360-3016 [Print] UNITED STATES
PMID10701730 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
Chemical References
  • Anti-Ulcer Agents
  • Antifungal Agents
  • Biomarkers
  • Radiation-Protective Agents
  • Sucralfate
  • Granulocyte-Macrophage Colony-Stimulating Factor
  • Lactoferrin
  • Administration, Oral
  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Ulcer Agents (administration & dosage, therapeutic use)
  • Antifungal Agents (therapeutic use)
  • Biomarkers (analysis)
  • Dose Fractionation
  • Female
  • Granulocyte-Macrophage Colony-Stimulating Factor (administration & dosage, therapeutic use)
  • Humans
  • Injections, Subcutaneous
  • Lactoferrin (analysis)
  • Leukopenia (etiology)
  • Male
  • Middle Aged
  • Pain Measurement
  • Patient Selection
  • Prospective Studies
  • Radiation Injuries (blood, complications, prevention & control)
  • Radiation-Protective Agents (administration & dosage, therapeutic use)
  • Saliva (chemistry)
  • Stomatitis (blood, etiology, prevention & control)
  • Sucralfate (administration & dosage, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: